Print Services: Subscribe | Home Delivery Web: Mobile Edition |

 
Site Web Search powered by YAHOO!SEARCH
 
Silicon Valley 150
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Gilead Sciences, Inc. (NQ: GILD)
56.30 USD  +1.34 (+2.44%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 55.48
Bid (Size) 56.29 (2700)
Ask (Size) 56.30 (25800)
Prev. Close 54.96
Today's Range 54.65 - 56.43
52wk Range 39.20 - 79.37
Shares Outstanding 1,525,355,825
Dividend Yield N/A
Top News
More News
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
May 17, 2013
from Business Wire News Releases
UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
May 17, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8350777 for the full story. Read More
from StreetInsider.com News Articles

More News
Read More
Analyst Moves: NOC, GM, GILD
May 17, 2013
category Stocks
from Market News Video
AbbVie (ABBV) Has Plenty More Tricks Up Its Sleeve - Barron's
May 17, 2013
from StreetInsider.com News Articles
Lightning Round: Starbucks, Gilead & More
May 16, 2013
category Lightning Round , Starbucks Corp , Dominion Resources Inc , and 10 more.
from CNBC.com News
Gilead anuncia datos de respuesta del estudio de Fase 2 de idelalisib para leucemia linfática crónica no tratada con anterioridad
May 16, 2013
from Business Wire Spanish
Strategy Behind Our Success, We Get in Early: GILD, MCP, GM and DF
May 16, 2013
from Marketwired News Releases
With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What
May 15, 2013
category NYSE:JNJ , NYSE:MRK , NASDAQ:PCYC , and 2 more.
from Forbes Real Time
Gilead Offers Response Data from Phase 2 Study of Idelalisib
May 15, 2013
category Benzinga , News , FDA , and 1 more.
from Latest Articles from Benzinga.com
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
May 15, 2013
from Business Wire News Releases
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Copyright 2008 San Jose Mercury News
Help | Site Map | Advertise | Newsletters | Home Delivery | Copyright | About MediaNews Group | RSS | Ethics Policy

Privacy Policy  |   Site Map